Labiotech.eu

Next-generation sequencing technologies have revolutionized the way scientific research is conducted, triggering new research paradigms and providing novel clinical insights. 🧬 This advent of next-generation sequencing has led to the rise of novel gene expression profiling methods like spatial transcriptomics. 💡 Labiotech spoke to Indivumed’s Maike Priester and Nicole Kerstedt, ReadCoor’s founder Richard Terry, 10x Genomics’ Malte Kuhnemund , and Curio Bioscience’s Neil Kennedy and Evan Macosko about the technology’s applications, challenges, and promise in various branches of medicine. 💊 How could this technology change the way we treat disease? Read our latest article to find out! 👇 https://lnkd.in/ekE9HCqx #NextGenSequencing #Genomics #SpatialTranscriptomics #BiomedicalResearch #GeneExpression #PrecisionMedicine 

Have you heard of switchable CAR-T therapies? 🔄 These next-generation CAR-T cells are aimed at overcoming the safety and efficacy limitations of conventional CAR-T products, like “on-target, off-tumor” effects and T cell exhaustion. 🦠⚡ They are able to be switched “on” and “off” even after they have been administered to the patient, meaning they are not constantly proliferating in the body, and the amount of CAR-T cell activity can be controlled, potentially from day-to-day, helping to reduce toxic side effects. 🌡️✅ Read our latest article to find out more about switchable CAR-T therapies! 👇 https://lnkd.in/dvdePrq6 #SwitchableCART #NextGenTherapies #cancertreatment #oncologyinnovation #biotech #immunotherapy #oncologyresearch #healthcareinnovation Scripps Research | AbbVie | AvenCell | Cellex Cell Professionals | Intellia Therapeutics, Inc. | Novo Holdings | BioNTech SE | Leucid Bio

What does patient-centric epilepsy care look like? 🔎 By integrating Patient-Reported Outcome Measures (PROMs) and fostering collaboration between patients and healthcare providers, Angelini Pharma is setting new standards in epilepsy care. Can this approach improve the quality of life for millions? ✅ Learn more about their patient-first initiatives in epilepsy treatment. ⬇️ https://lnkd.in/d3KzsiKi #epilepsycare #genetherapy #epilepsyresearch #pharmainnovation #healthcareadvances #scientificbreakthroughs #neuroscience

G protein-coupled receptors (GPCRs) are the largest and most diverse group of membrane receptors in the body. 📡🧬 Many drugs and biologics target GPCRS, including allergy medicines such as antihistamines, pain relief drugs, and diabetes treatments. 💊 Still, around 75% of GPCR therapeutic targets are yet to be drugged, representing untapped opportunities for drug discovery and development to address numerous diseases. 🔍 We take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused pipelines, most of which have hit the clinic. 🏥 Read our latest article to find out! 👇 https://lnkd.in/dFSsArxA #GPCR #drugdiscovery #biotech #pharmainnovation #healthcareinnovation #biotechnews Confo Therapeutics | Domain Therapeutics | Escient Pharmaceuticals | Orion Biotechnology | Septerna | Structure Therapeutics | Tectonic Therapeutic, Inc. | Teon Therapeutics Inc.

Weekly Recap of the Hottest Partnerships in the Biotech World! 🔥🤝 Partnering: 🤝 🇨🇳 Chengdu Baiyu Pharmaceutical signs licensing agreement with 🇨🇭 Novartis for a small molecule to treat cancer | Baiyu to receive $70 million upfront and can receive up to $1.1 billion in milestone payments   🇫🇷 Sanofi and 🇫🇷 Orano Med collaborate to develop radioligand medicines to treat cancer | Sanofi to make an equity investment of €300 million ($323.95 million)  🇺🇸 Editas Medicine and 🇨🇦 Genevant Sciences to collaborate to develop gene editing therapeutics | Genevant to receive up to $238 million in upfront and contingent milestone payments  🇬🇧 Avacta and 🇺🇸 Tempus AI collaborate to advance AI-driven drug development for cancer | undisclosed financial terms 🇺🇸 Bright Minds Biosciences and 🇺🇸 🇨🇦 Firefly Neuroscience to collaborate to provide EEG data for a phase 2 trial testing a drug to treat absence epilepsy and developmental epileptic encephalopathy | undisclosed financial terms  🇬🇧 Nucleome Therapeutics collaborates with 🇺🇸 Johnson & Johnson to map genetic associations linked to autoimmune disease | undisclosed financial terms  Subscribe to our newsletter for more partnering updates!  🔗 https://lnkd.in/dsgz62YY #deals #partnering #mergers #acquisitions #biotech

Have you heard about lab-grown fish? 🐠 Since the breakthrough approval of cultured meat in Singapore and the U.S., the idea of growing food items from cells in a petri dish has grown in scope. 🌎 Now, several lab-grown fish startups are coming to the fore, in an attempt to tackle issues such as overfishing and an increased demand for seafood by creating sustainable, cultivated fish products.🌱 Read our latest article to find out everything you need to know about the lab-grown fish field! 👇 https://lnkd.in/duitVdC9 #culturedmeat #labgrown #sustainability #sustainableeating #foodinnovation    “foodtech #labgrownmeat #sustainablefood #bioproduction #futureoffood #cellagriculture #culturedfish #cultivatedfish The Good Food Institute | New Harvest | BLUU Seafood | Wanda Fish | Umami Bioworks | BlueNalu | Wildtype 

Did you know that space travel can impact kidney health? 🌌  👩🚀 The kidneys are highly sensitive to radiation and microgravity can cause fluid shifts and damage to mitochondria, which affect kidney function. British biotech LinkGevity was selected for the NASA - National Aeronautics and Space Administration Space-H Accelerator program to develop medicines that can support human deep-space missions. 🚀 💬 This week, we spoke to LinkGevity’s CEO Dr. Carina Kern and COO Serena Kern-Libera about the company’s anti-necrotic technology, which is being designed to treating kidney disease. 🎧 Tune in to the latest episode of the Beyond Biotech Podcast to learn more! 👇 https://lnkd.in/d8NVDXGi Starburst | Aerospace Medical Association | Translational Research Institute for Space Health | International Space Medicine Consortium #biotechstartup #biotech #accelerator #biopharma #kidneydisease #kidneyhealth #spacemedicine #healthinspace #mitochondria

💰 Biotech's Top Investments This Week! 🚀 🇺🇸 Seaport Therapeutics | $225 million series B | neuropsychiatric medicines | phase 2 in major depressive disorder 🇺🇸 Terray Therapeutics | $120 million series B | AI-driven drug discovery | preclinical in immunological diseases 🇺🇸 AvenCell | $112 million series B | CAR-T cell therapy | phase 1/2 in acute myeloid leukemia 🇺🇸 Be Biopharma | $82 million financing | engineered B cell therapies | phase 1/2 in hemophilia B 🇺🇸 Capricor Therapeutics, Inc. | $75 million public offering | exosome-based therapeutics | phase 3 in Duchenne muscular dystrophy 🇬🇧 🇺🇸 Nuclera | $75 million series C | protein expression 🇨🇦 Bright Minds Biosciences | $35 million private placement | central nervous system therapies | phase 2 in rare epilepsies 🇬🇧 ikarovec | £5 million seed | gene therapy | preclinical in geographic atrophy 🇺🇸 BioVie Inc. | $6.66 million ($6.49 million) registered direct offering and concurrent private placement | liver disease and neurological therapies | clinical in liver cirrhosis Subscribe to our newsletter for more fundraising updates! 🔗 https://lnkd.in/dsgz62YY #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding

Is the next decade going to change the Dravet syndrome treatment landscape? 🤔 The most recent development in this space is Lundbeck’s acquisition of Longboard Pharmaceuticals and its lead candidate – bexicaserin – a late-stage asset in developmental and epileptic encephalopathies including Dravet syndrome. With an estimated launch in 2028, Lundbeck hopes that bexicaserin will become a cornerstone of its neuro-rare disease portfolio. 💰 But Lundbeck and Longboard aren’t the only ones making waves and the field is actually gaining momentum. With a mix of therapies focused primarily on seizure reduction and treatments addressing the root cause of Dravet syndrome, find out who might bring the next game-changing option to patients. 🚀 Read more below! ⬇️ https://lnkd.in/d2vmENtq #DravetSyndrome #neurorarediseases #epilepsytreatment #epilepsyawareness #innovativetherapies #neurologyresearch Johan Luthman | GW Pharmaceuticals plc | BIOCODEX | Zogenix, Inc. | Harmony Biosciences | Epygenix Therapeutics, Inc. | Takeda | Stoke Therapeutics | Encoded Therapeutics Inc.

In the ever-evolving biotech landscape, associations play a crucial role in connecting the dots between biotech companies, pharmaceutical firms, academic institutions, research organizations, policymakers, and investors. They foster collaboration, technology transfer, and partnerships, driving innovation and growth in the industry. 🤝 We’ve put together a list of biotech associations by country and specialization to support your expansion efforts. 🌍 Check out who’s on the list and see how these organizations may support your initiatives. 👇 https://lnkd.in/d-bpmSUe #Biotech #Biopharma #Associations #Partnerships #Collaboration #Innovation #Techtransfer #Drugdevelopment #Biotechindustry AseBio - Asociación Española de Bioempresas | KoreaBIO | France Biotech | EuropaBio - the European Association for Bioindustries | BIOTECH AUSTRIA | Swiss Biotech Association | Biotechnology Innovation Organization | BIOTECanada | ChileBio | ArgenBio | AusBiotech | bio.be | DANISH BIO - DANSK BIOTEK | BIO Deutschland e. V. | Assobiotec | hollandbio | P-BIO - Associação Portuguesa de Bioindústria | BioIndustry Association (BIA)